171 related articles for article (PubMed ID: 30861114)
1. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.
Landy R; Schiffman M; Sasieni PD; Cheung LC; Katki HA; Rydzak G; Wentzensen N; Poitras NE; Lorey T; Kinney WK; Castle PE
Int J Cancer; 2020 Feb; 146(3):617-626. PubMed ID: 30861114
[TBL] [Abstract][Full Text] [Related]
2. Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
Befano B; Wentzensen N; Lorey T; Poitras N; Cheung LC; Schiffman M; Clarke MA; Cohen C; Kinney W; Locke A; Castle PE
Gynecol Oncol; 2024 May; 184():89-95. PubMed ID: 38301311
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting.
Austin RM; Onisko A; Zhao C
Am J Clin Pathol; 2018 Oct; 150(5):385-392. PubMed ID: 30137189
[TBL] [Abstract][Full Text] [Related]
4. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
[TBL] [Abstract][Full Text] [Related]
5. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
6. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
[TBL] [Abstract][Full Text] [Related]
7. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
8. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
[TBL] [Abstract][Full Text] [Related]
9. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
Orumaa M; Leinonen MK; Campbell S; Møller B; Myklebust TÅ; Nygård M
Int J Cancer; 2019 Nov; 145(10):2629-2638. PubMed ID: 30734284
[TBL] [Abstract][Full Text] [Related]
10. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
12. Why does cervical cancer occur in a state-of-the-art screening program?
Castle PE; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Schiffman M
Gynecol Oncol; 2017 Sep; 146(3):546-553. PubMed ID: 28606721
[TBL] [Abstract][Full Text] [Related]
13. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
[TBL] [Abstract][Full Text] [Related]
14. Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States.
Cuzick J; Adcock R; Kinney W; Castle PE; Robertson M; McDonald RM; Stoler MH; Du R; Wheeler CM;
Int J Cancer; 2023 Jul; 153(1):83-93. PubMed ID: 36946690
[TBL] [Abstract][Full Text] [Related]
15. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
[TBL] [Abstract][Full Text] [Related]
16. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
17. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
[TBL] [Abstract][Full Text] [Related]
18. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
19. Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.
Castle PE; Kinney WK; Xue X; Cheung LC; Gage JC; Zhao FH; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Katki HA; Schiffman M
Ann Intern Med; 2018 Jan; 168(1):20-29. PubMed ID: 29181509
[TBL] [Abstract][Full Text] [Related]
20. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
